Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Link
https://link.springer.com/content/pdf/10.1007/s10157-022-02192-2.pdf
Reference32 articles.
1. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–85. https://doi.org/10.1056/NEJMcp0804458.
2. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18. https://doi.org/10.1056/NEJMoa1205511.
3. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930–42. https://doi.org/10.1056/NEJMoa1710030.
4. Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458–70. https://doi.org/10.1681/ASN.2018060590.
5. Reddy B, Chapman AB. Acute response to tolvaptan in ADPKD: a window to predict long-term efficacy? Am J Kidney Dis. 2015;65(6):811–3. https://doi.org/10.1053/j.ajkd.2015.03.004.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD;Nephrology Dialysis Transplantation;2023-11-03
2. Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease;Clinical and Experimental Nephrology;2023-06-27
3. Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre;Clinical Kidney Journal;2022-08-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3